NCT03525925View on ClinicalTrials.gov

Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 18, 2018

Primary Completion Date

February 20, 2020

Study Completion Date

July 31, 2022

Conditions
Metastatic Malignant Solid Neoplasm
Interventions
DRUG

Ibrutinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT03525925 - Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter